Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04030572 · ClinicalTrials.gov registry record · Early Phase 1

Feasibility of Administering Clonidine as a Pharmacological Challenge in Imaging Studies

A Early Phase 1 study, sponsored by Weill Medical College of Cornell University.

Terminated
Registry status
Early Phase 1
Development phase
3
Enrollment target

NCT04030572 is a Early Phase 1 study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 3 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04030572, a Early Phase 1 study, was terminated before completion, sponsored by Weill Medical College of Cornell University.

TERMINATED
Registry status
Early Phase 1
Development phase
3 participants
Enrollment target

Study Summary

This will be a Phase 1, open label study of the pharmacokinetics (PK) and pharmacodynamics (PD) of clonidine, an alpha-2 adrenergic (a2a) agonist, in healthy volunteers. The primary aim is to show that the drug regimen is safe and reasonably well tolerated. The secondary aim is to demonstrate that safety can be monitored with home health devices.

Interventions

  • DRUG Clonidine Pill

Trial Details

FieldValue
Enrollment Target 3 participants
Start Date 2019-12-10
Est. Completion 2020-03-17
Phase Early Phase 1

What the Registry Record Tells You About NCT04030572

The ClinicalTrials.gov registry entry for NCT04030572 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Clonidine Pill is the first listed.

NCT04030572 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04030572 about?

NCT04030572 is a clinical study titled "Feasibility of Administering Clonidine as a Pharmacological Challenge in Imaging Studies". This will be a Phase 1, open label study of the pharmacokinetics (PK) and pharmacodynamics (PD) of clonidine, an alpha-2 adrenergic (a2a) agonist, in healthy volunteers. The primary aim is to show that the drug regimen is safe and reasonably well tolerated. The secondary aim is to demonstrate that s...

What is the current status of trial NCT04030572?

This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 3 participants. The study started on 2019-12-10. Estimated completion is 2020-03-17.

What interventions are being tested in trial NCT04030572?

The interventions under investigation include: Clonidine Pill (DRUG).

Who is sponsoring clinical trial NCT04030572?

This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.